Using Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Joshua Richter, MD, discusses the evolving treatment landscape in relapsed/refractory multiple myeloma.

EP. 1: Overview of Multiple Myeloma and Treatment Options

January 20th 2023

Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.

EP. 2: Role of Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

January 20th 2023

Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.

EP. 3: Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM

January 27th 2023

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

EP. 4: Bispecific Antibodies in the Treatment of Multiple Myeloma

January 27th 2023

An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.

EP. 5: Clinical Pearls and Unmet Needs in R/R Multiple Myeloma

February 3rd 2023

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.